Tag: cyclic nucleotide phosphodiesterases
The German biotech company biocrea GmbH today announced the expansion of its management team by appointing Martin Gunthorpe (formerly GlaxoSmithKline, GSK) as Chief Scientific Officer, Viktor Viehweg (formerly Sibur Ltd.) to the position of Chief Financial Officer, and Simon Ward (formerly GSK) to Executive Vice President Chemistry & Development.
biocrea was established in November 2010 following a management buy-out from Biotie Therapies Corp. (HSE: BTH1V; Turku, Finland). In the transaction, biocrea acquired the CNS pipeline and a cyclic nucleotide phosphodiesterase (PDE) inhibitor platform from Biotie. biocrea’s team has a long-standing, exceptional track record in the development of CNS therapeutics, e.g. the development of a PDE10 inhibitor portfolio for the treatment of schizophrenia in collaboration with Wyeth Pharmaceuticals and Pfizer, which acquired Wyeth in 2009. The company plans to expand its pipeline and to obtain attractive assets in order to build a more mature portfolio. Already, it is in advanced negotiations with several pharma partners, such as GSK.
biocrea’s management will attend the J.P. Morgan 29th Annual Healthcare Conference 2011, San Francisco, January 10-13, 2011. If you wish to make an appointment, please contact akampion via email@example.com.